Head-to-head · freedom premium vs tier ladder
Henry Meds vs ShedRx: what exit freedom costs, what the ladder charges
Two expensive philosophies. Henry prices freedom: true month-to-month at ~$149 semaglutide / ~$249 tirzepatide — no term, no tiers, and a tirzepatide year near $2,988. ShedRx prices the ladder: entry near $199 tiering toward $299 at maintenance, a realistic year near $3,388 — with a brand hand-off lane as its genuine ace. Both lose the cash arithmetic to the audited flats by four figures; each keeps one honest niche.
The freedom premiumHenry
M2M means month one and month nine cost the same and leaving costs nothing — clean, legible, and priced at a premium: ~$2,988 tirzepatide / ~$1,788 semaglutide per year. You are buying the exit, monthly. ON RECORD
The ladderShedRx
$199 at the door, $299 where maintenance lives — the step-up tax in its clearest form, ~$3,388 realistic year. Its ace: the insurance hand-off to covered brand mid-journey, which can beat every cash figure when PA clears. ON RECORD
Head to headThe math
Tirzepatide year: Henry ~$2,988 vs ShedRx ~$3,388 — Henry wins by ~$400 and keeps the exit. ShedRx's counter is entirely the coverage lane; without live insurance, the ladder is just the more expensive door.
The uncomfortable cardThe benchmark
The audited flat runs $1,668 with the same monthly exit freedom Henry charges a premium for (30 days' notice) — which prices Henry's "freedom premium" at ~$1,300/year for freedom the benchmark includes. That sentence is the whole comparison.
The verdict, as a rule: live insurance that might approve brand → ShedRx's hand-off (or Ro's navigator) earns a deadlined test. Otherwise: between these two, Henry — cheaper and freer. Against the field: neither survives the audited flat, which matches Henry's exit terms at $1,320 less per year on tirzepatide. Compounded product carries no FDA review; molecule fit is a clinician's call — the constants don't change by matchup.
Henry — true month-to-month ↗ ShedRx — the brand lane ↗ The audited flat benchmark ↗
Partner links carry sponsored tags; the math predates the links. How the money works.
Is Henry Meds or ShedRx cheaper?
For cash tirzepatide, Henry — ~$2,988/year month-to-month versus ShedRx's ~$3,388 realistic tiered year — while also keeping exit freedom. ShedRx's advantage is its insurance hand-off lane when prior authorization is plausible.
What does Henry's month-to-month premium buy?
A no-term exit and dose-flat billing — legible freedom priced ~$1,300/year above the audited flat benchmark, which offers the same 30-day exit at $1,668.
When is ShedRx the right pick anyway?
When live commercial insurance might approve brand Zepbound — the mid-journey hand-off to a covered copay can beat every cash price in the field.
More head-to-heads: NexLife vs ShedRx · Mochi vs Henry · NexLife vs Hims · Hims vs Ro